B Riley

All eyes are on Nike Inc (NYSE: NKE) sales heading into its first-quarter earnings report Wednesday, Sept. 25, the first since the company launched its "Just Do It" campaign featuring Colin Kaepernick. Here's what analysts are saying ahead of the print.  Baird Stays...

With Urban Outfitters Inc (NASDAQ: URBN) coming off a strong second-quarter earnings beat and record sales, Wall Street analysts came in droves to discuss the retailer's future prospects.  Analyst Ratings: Nomura analyst Simeon Siegel maintained a Neutral rating on Urban Outfitters...

A little more than a year after its initial public offering, Tocagen Inc (NASDAQ: TOCA) has traded down 26 percent, but experts are decidedly bullish on the company’s prospects and potential valuation. The Rating B Riley analyst Madhu Kumar initiated coverage on Tocagen with a Buy rating...

Carvana Co (NYSE: CVNA) is up 160 percent year-over-year, and one seller is signing on for the continuing momentum.  The Rating B. Riley FBR analyst Sameet Sinha upgraded Carvana from Sell to Buy and increased the price target from $20 to $38. The Thesis Sinha identified particular “...

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) continued to decline after Pfizer Inc. (NYSE: PFE) reported its transthyretin stabilizer Vyndaqel met primary Phase 3 endpoints Thursday. However, B Riley FBR considers the ostensible competitor’s victory a positive for Alnylam. The Rating...

Lululemon Athletica inc. (NASDAQ: LULU) were up more than 9 percent at the close Wednesday following a fourth-quarter earnings beat that saw comps up a remarkable 12 percent. The athletic apparel maker reported a Q4 adjusted EPS of $1.33 against a $1.27 estimate, sales of $928.8 million versus the...

Nike Inc (NYSE: NKE) is set to report earnings after the close on Thursday, March 22, one week after competitor adidas AG (ADR) (OTC: ADDYY) announced another quarter of double-digit growth in North America. B Riley Stays Neutral  With Nike's promotional activity remaining high in North...

Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) announced Tuesday that the U.S. Food and Drug Administration accepted a New Drug Application for eravacycline, an antibiotic for complicated intra-abdominal infection, for priority review. Traders initially reacted positively, and so did analysts. The...

A comeback in denim could fuel significant upside for Guess?, Inc. (NYSE: GES) in coming years, a B Riley FBR analyst said in a Monday upgrade note.  The Analyst Susan Anderson of B Riley upgraded Guess from Neutral to Buy rating and with a $20 price target.  The Thesis When...

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH)’s kinase switch control platform has largely gone unnoticed on the Street. The nascent portfolio caught an analyst's attention this week.  The Rating B Riley analyst Madhu Kumar initiated coverage on Deciphera with a Buy rating and $43...